Hwail Pharm Co Ltd
KOSDAQ:061250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gold Hydrogen Ltd
ASX:GHY
|
AU |
|
Toda Corp
TSE:1860
|
JP |
|
T
|
TASCO Bhd
KLSE:TASCO
|
MY |
|
K
|
Kinik Co
TWSE:1560
|
TW |
|
Concraft Holding Co Ltd
TWSE:4943
|
TW |
|
S
|
Shanghai Tianyong Engineering Co Ltd
SSE:603895
|
CN |
Hwail Pharm Co Ltd
Total Current Liabilities
Hwail Pharm Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
Total Current Liabilities
₩5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-17%
|
|
|
Yuhan Corp
KRX:000100
|
Total Current Liabilities
₩733.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Current Liabilities
₩295.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Current Liabilities
₩605.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Current Liabilities
₩89.2B
|
CAGR 3-Years
41%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Total Current Liabilities
₩8.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Hwail Pharm Co Ltd
Glance View
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Hwail Pharm Co Ltd's Total Current Liabilities?
Total Current Liabilities
5B
KRW
Based on the financial report for Dec 31, 2025, Hwail Pharm Co Ltd's Total Current Liabilities amounts to 5B KRW.
What is Hwail Pharm Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-17%
Over the last year, the Total Current Liabilities growth was -57%. The average annual Total Current Liabilities growth rates for Hwail Pharm Co Ltd have been -14% over the past three years , -17% over the past five years , and -17% over the past ten years .
